Mayor thromboembolic complications during oral anticoagulant therapy: Importance of treatment intensity;Complicaciones tromboembólicas mayores durante el tratamiento con anticoagulantes orales: Importancia del nivel de anticoagulación

Sangre

Volumn 44, Issue 6, 1999, Pages 469-472

  De Vicente Cámara, M Pilar ^a   Cuesta, José Félix Lucía ^a   Franco, Carlos Aguilar ^a   Bernad, Víctor Solano ^a   González, Carolina Serrano ^a   García Erce, José Antonio ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 0033291678     PISSN: 00364355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Schofield FW. Damaged sweet clover; the cause of a new disease in cattle simulating haemorrhagic septicemia and blackleg. J Am Vet Med Ass 1924; 64: 553.
2. Roderick LM. A problem in the coagulation of the blood; "sweet clover disease of the cattle". Am J Physiol 1931; 96: 413-425.
3. Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
4. Gitter MJ, JaegerTM, Petterson TM, Gersh BJ, Phil Ch.B, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochesta, Minnesota. Mayo Clin Proc 1995; 70: 725-733.
5. Alonso R, Puche N, de la Fuente MD, Serrano P, García L. Control de calidad terapeútico del seguimiento de la anticoagulación oral en atención primaria: cuatro años de expericncia. Atención primaria 1995; 15: 27-32.
6. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation. A multi-center study. Ann Intern Med 1993; 118: 511-520.
7. Katsuki T, Saito M, Noda T, Yaginuma T, Hosoda S. Long-term follow-up in patients receiving anticoagulation therapy: Potency of therapy and complications. J Cardiol 1994; 24: 203-209.
8. Schulman S and the Duration of Anticoagulation (DURAC) Trial Study Group. Quality of oral anticoagulant control and treatment in Sweden. J Intern Med 1994; 236: 143-152.
9. Dalen JE, Hirsh J. ACCP-NHBI. National Conference on Antithrombotic Therapy. Chest 1986; 89 (suppl): 1 S-106 S.
10. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992; 102 (suppl): 312S-326S.
11. Dalen JE, Hirsh J. ACCP-NHLBI. National Conference on Antithrombotic Therapy. Chest 1986; 89 (suppl): 1 S-106 S.
12. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25: 1111-1119.
13. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641.
14. Cannegieter SC, Rosendaal FR, Wintzen AR, Van Der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.